Ifm Investors Pty LTD Seagen Inc. Transaction History

Ifm Investors Pty LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 26, 2023	BUY	$191.51 - $216.16 $179,061 - $202,109	935 Added 3.46%	27,941 $5.93 Million
Q2 2023 Jul 27, 2023	SELL	$187.64 - $206.25 $5,629 - $6,187	-30 Reduced 0.11%	27,006 $5.2 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $57,160 - $90,979	448 Added 1.68%	27,036 $5.47 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $119,600 - $141,814	1,019 Added 3.99%	26,588 $3.42 Million
Q3 2022 Oct 12, 2022	BUY	$135.27 - $180.11 $110,109 - $146,609	814 Added 3.29%	25,569 $3.5 Million

Q2 2022 Jul 15, 2022	BUY	$108.81 - $179.33 $352,544 - $581,029	3,240 Added 15.06%	24,755 $4.38 Million
Q1 2022 Apr 13, 2022	BUY	$119.61 - $157.85 $412,654 - $544,582	3,450 Added 19.1%	21,515 $3.1 Million
Q4 2021 Jan 18, 2022	BUY	$142.57 - $190.86 $13,686 - $18,322	96 Added 0.53%	18,065 $2.79 Million
Q2 2021 Jul 16, 2021	BUY	$135.08 - $161.1 $451,842 - $538,879	3,345 Added 22.87%	17,969 $2.84 Million
Q1 2021 May 05, 2021	BUY	$137.51 - $190.8 $415,555 - $576,597	3,022 Added 26.05%	14,624 $2.03 Million
Q4 2020 Jan 13, 2021	BUY	$164.63 - $211.93 $1.91 Million - $2.46 Million	11,602 New	11,602 $2.03 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Ifm Investors Pty LTD with notifications on news.